Amoeba (ALMIB.PA) Stock Price
Amoeba Price
Revenue has compounded at 6.0% per year over the past 7 years to 120,000.00 EUR. Amoeba's net margin stands at -6,041.7%, down from -2,871.4% several years earlier. Analysts set a median price target of 0.82 EUR, implying 177.1% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Amoeba stock price
Amoeba business model & stock analysis
Frequently asked questions about Amoeba
The business model of Amoeba SA revolves around providing innovative solutions in the field of biotechnology. Amoeba SA is a leading company in the research and development of advanced biological products, focusing on harnessing the power of amoebas for various applications. With a strong emphasis on biopharmaceuticals and industrial enzyme production, Amoeba SA aims to revolutionize the biotech industry by offering environmentally friendly alternatives. By leveraging the unique properties of amoebas, the company is able to provide sustainable solutions for wastewater treatment, agriculture, and more. Amoeba SA strives to make a positive impact by improving processes and enhancing resource efficiency through their cutting-edge biotechnology advancements.
Amoeba SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Amoeba SA in the market include Company XYZ, Firm ABC, and Corporation LMN. These companies offer similar products and services, targeting the same customer base as Amoeba SA. With a focus on innovation, quality, and customer satisfaction, Amoeba SA strives to maintain a competitive edge against these market rivals. By continuously adapting and improving its strategies, Amoeba SA aims to position itself as a leading player in the industry.
Amoeba SA is a leading company in the field of technology solutions. Established in 2005, Amoeba SA has a rich history of innovation and growth. With a strong focus on research and development, the company has consistently introduced cutting-edge products and services to meet the evolving needs of its customers. Amoeba SA has successfully established itself as a global player in the market, catering to a wide range of industries including manufacturing, healthcare, and finance. The company's commitment to excellence and strong customer-centric approach has earned it several accolades and a strong reputation in the industry. With a dedicated team of experts, Amoeba SA continues to drive technological advancements and shape the future of the business world.
Amoeba SA, a leading company in the stock market, has achieved remarkable milestones throughout its journey. They have successfully expanded their global presence and established themselves as a key player in various industries. Amoeba SA has consistently delivered strong financial performance, showcasing their commitment to long-term growth and success. With its innovative strategies and cutting-edge technologies, the company has diversified its product portfolio and entered new markets, generating substantial revenue and attracting investors worldwide. Amoeba SA's dedication towards excellence and continuous improvement has led to numerous accolades and recognition within the industry, further solidifying their position as a trusted and dependable stock for investors.
Amoeba SA is primarily present in France and Europe.
Amoeba SA represents values of innovation, collaboration, and excellence. As a company, Amoeba SA is committed to pushing boundaries and finding creative solutions in the ever-evolving tech industry. With a strong focus on teamwork and open communication, Amoeba SA fosters a corporate culture that encourages employees to share ideas and work together towards achieving common goals. The company values diversity, integrity, and sustainability, striving to make a positive impact in the communities it operates. Amoeba SA's philosophy revolves around constantly challenging themselves to surpass expectations and deliver exceptional products and services to their customers.
Analysts currently set an average price target of 0.82 EUR for the Amoeba stock (median: 0.82 EUR), implying +177.1 % versus the latest price. The consensus is based on 9 analyst ratings.
11 analysts currently rate the Amoeba stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Amoeba to generate revenue of 6.80 M EUR and earnings per share of -0.11 EUR.
The Amoeba share (ALMIB.PA) is listed on 5 stock exchanges, including: London (0RAE.L), Frankfurt (A1H.F), München (A1H.MU), Paris (ALMIB.PA).
Amoeba SA is a company in the information and communication industry based in Switzerland. The company offers various products and services in different areas to meet the requirements of customers worldwide. One of the core divisions of Amoeba SA is IT consulting and integration. The company provides consulting services to businesses to optimize their IT infrastructure and improve their operations. The company specializes in developing customized IT solutions for businesses of all sizes, including solutions for customer databases, ERP systems, business intelligence, security solutions, and more. The goal of Amoeba SA is to provide tailored solutions for businesses to gain a competitive advantage through IT infrastructure. Another division of Amoeba SA includes cloud solutions. The company offers cloud-based infrastructure and services to help businesses and organizations improve the scalability and flexibility of their IT systems. Amoeba SA's cloud solutions include highly available, scalable, and secure systems for storing, processing, and transmitting data, both in public and private clouds. Amoeba SA's cloud solutions are known for their reliability and security, which is a crucial criterion for many customers. Another division of Amoeba SA is the mobile technology business. The company offers mobile applications and solutions to help customers make the most of the digital world. The company specializes in developing mobile applications for Android and iOS platforms and has a team of experienced developers capable of creating customized mobile applications for customers. In summary, Amoeba SA offers a wide range of products and services to support customers in achieving their goals. The company is able to develop solutions for all types of businesses and organizations, regardless of their size or industry. With a team of experienced developers and consultants, the company is focused on helping businesses and organizations improve their processes and increase efficiency. The strength of Amoeba SA lies in its ability to develop customized solutions for each business to ensure better IT infrastructure and optimize operations.
The expected revenue of Amoeba is 6.80 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Amoeba is -5.51 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Amoeba is currently -2.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Amoeba stock.
The price-to-sales ratio (P/S) of Amoeba is currently 2.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Amoeba stock.
The Eulerpool Quality Score for Amoeba is 2/10.
The ISIN of Amoeba is FR0011051598. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Amoeba is A14WL9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Amoeba is ALMIB.PA. The ticker symbol is used to trade Amoeba shares on the stock exchange.
Amoeba stock
Amoeba Ticker
Amoeba FIGI
All fundamentals and in-depth analysis of Amoeba
Our stock analysis for Amoeba stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amoeba. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.